38 research outputs found

    A study on the heavy payloads underwater manipulator for deep-sea driven by electric motor

    Get PDF
    In this study, a development of a 6 D.O.F underwater manipulator which is actuated by electric motors capable of carrying over 70kg payload. It designed to be driven at 3,000m. Balancing weight is applied to reduce the capacity of the joint-2 actuator. I calculated the ideal motor capacity by interpreting inertia torque where is on the each joint actuator. The joint actuator for the manipulator is designed as a double oil jacket for waterproofness in high pressure. Each link is designed the modularization to assemble and replace the parts easily. The kinematics and dynamics of the manipulator has been analyzed based on new designed manipulator. By doing this, I can figured out the feature of 6-axis manipulator motion and stability evaluation of link structure. Also, Thickness of link cylinder at 3,000m has been verified through FEM simulation.1. μ„œ λ‘  1.1 κ°œμš” 1.2 κΈ°μ‘΄ λ§€λ‹ˆν“°λ ˆμ΄ν„° 뢄석 1.2.1 μœ μ•• ꡬ동 λ°©μ‹μ˜ μˆ˜μ€‘ λ§€λ‹ˆν“°λ ˆμ΄ν„° 1.2.2 μ „κΈ° λͺ¨ν„° λ°©μ‹μ˜ μˆ˜μ€‘ λ§€λ‹ˆν“°λ ˆμ΄ν„° 1.3 μ—°κ΅¬λ²”μœ„ 및 λͺ©μ  2. μˆ˜μ€‘ λ§€λ‹ˆν“°λ ˆμ΄ν„°μ˜ ꡬ쑰섀계 2.1 μˆ˜μ€‘ 6μΆ• λ§€λ‹ˆν“°λ ˆμ΄ν„°μ˜ ꡬ성 및 섀계쑰건 2.2 μˆ˜μ€‘ 6μΆ• λ§€λ‹ˆν“°λ ˆμ΄ν„°μ˜ κ΄€μ ˆκ΅¬λ™κΈ° μš©λŸ‰μ„€κ³„ 2.2.1 각 κ΄€μ ˆμ˜ κ΄€μ„±λͺ¨λ©˜νŠΈ κ°€μ • 및 해석 2.2.2 각 κ΄€μ ˆμ˜ 각속도 및 각가속도 해석 2.2.3 각 κ΄€μ ˆμ˜ κ΄€μ„±λ ₯에 μ˜ν•œ 토크 해석 2.2.4 λ§ν¬μ€‘λŸ‰μ— μ˜ν•΄ λ°œμƒν•˜λŠ” 각 κ΄€μ ˆμ˜ 토크 해석 2.2.5 ν•­λ ₯에 μ˜ν•΄ λ°œμƒν•˜λŠ” 각 κ΄€μ ˆμ˜ 토크 해석 2.2.6 각 κ΄€μ ˆμ˜ κ΄€μ„±λ ₯κ³Ό 무게, ν•­λ ₯에 μ˜ν•œ 토크 해석 2.3 κ΄€μ ˆκ΅¬λ™κΈ° 기ꡬꡬ쑰 섀계 2.3.1 κ΄€μ ˆκ΅¬λ™κΈ°μ˜ μˆ˜λ°€κ΅¬μ‘° 2.3.2 κ΄€μ ˆκ΅¬λ™κΈ° λ°°μΉ˜μ„€κ³„ 2.4 μˆ˜μ€‘ 6μΆ• λ§€λ‹ˆν“°λ ˆμ΄ν„°μ˜ 기ꡬ뢀 섀계 3. μˆ˜μ€‘ 6μΆ• λ§€λ‹ˆν“°λ ˆμ΄ν„°μ˜ 기ꡬ학 및 동역학 해석 3.1 λ§€λ‹ˆν“°λ ˆμ΄ν„°μ˜ μˆœκΈ°κ΅¬ν•™ 해석 3.2 λ§€λ‹ˆν“°λ ˆμ΄ν„°μ˜ 역기ꡬ학 해석 3.3 λ§€λ‹ˆν“°λ ˆμ΄ν„°μ˜ 속도 기ꡬ학 해석 3.4 λ§€λ‹ˆν“°λ ˆμ΄ν„°μ˜ 동역학 해석 4. μˆ˜μ€‘ 6μΆ• λ§€λ‹ˆν“°λ ˆμ΄ν„° 링크의 μœ ν•œμš”μ†Œν•΄μ„ 4.1 λ§€λ‹ˆν“°λ ˆμ΄ν„°μ˜ 링크 싀린더 λ‚΄μ•• 해석 4.1.1 싀린더 λͺ¨λΈλ§κ³Ό 경계쑰건 4.1.2 싀린더 μ••λ ₯ 해석 κ²°κ³Ό 4.1.3 싀린더 쒌꡴ 해석 κ²°κ³Ό 5. κ²°λ‘  μ°Έκ³ λ¬Έ

    취업여뢀에 λ”°λ₯Έ κΈ°ν˜Όμ—¬μ„±μ˜ μΆ”κ°€ μΆœμ‚°μ˜ν–₯

    Get PDF
    ν•™μœ„λ…Όλ¬Έ (석사)-- μ„œμšΈλŒ€ν•™κ΅ λŒ€ν•™μ› : κ²½μ œν•™λΆ€, 2013. 2. λ₯˜κ·Όκ΄€.λ³Έ μ—°κ΅¬λŠ” μš°λ¦¬λ‚˜λΌ κΈ°ν˜Όμ—¬μ„±μ˜ 취업여뢀에 따라 경제적, λ¬Έν™”κ°€μΉ˜κ΄€, 지역적 νŠΉμ„±μ΄ μΆ”κ°€μΆœμ‚°μ˜ν–₯에 λ―ΈμΉ˜λŠ” 영ν–₯을 μ•Œμ•„λ³΄κ³ μž ν•˜μ˜€λ‹€. 뢄석을 μœ„ν•΄ ν†΅κ³„μ²­μ˜ 2005λ…„ 인ꡬ주택총쑰사 λ§ˆμ΄ν¬λ‘œλ°μ΄ν„°λ₯Ό ν™œμš©ν•˜μ˜€κ³  만 20-40μ„Έ κΈ°ν˜Όμ—¬μ„± 76,385λͺ…을 λŒ€μƒμœΌλ‘œ ν•˜μ—¬ ν”„λ‘œλΉ— νšŒκ·€ λͺ¨ν˜•μ„ μ‚¬μš©ν•˜μ˜€λ‹€. 뢄석 κ²°κ³Ό, 경제적, λ¬Έν™”κ°€μΉ˜κ΄€ λ³€μˆ˜λΏλ§Œ μ•„λ‹ˆλΌ 지역별 λ³€μˆ˜κ°€ μΆ”κ°€ μΆœμ‚°μ˜ν–₯에 영ν–₯을 λ―ΈμΉ˜λŠ” κ²ƒμœΌλ‘œ λ‚˜νƒ€λ‚¬λ‹€. 지역별 μ‹€μ—…λ₯ μ€ μ·¨μ—…μ—¬μ„±κ³Ό λ―Έμ·¨μ—…μ—¬μ„±μ˜ μΆ”κ°€ μΆœμ‚°μ˜ν–₯을 κ°μ†Œμ‹œν‚€λŠ” κ²ƒμœΌλ‘œ λ‚˜νƒ€λ‚¬μœΌλ©° λ³΄μœ‘μ‹œμ„€ 곡급λ₯  λ³€μˆ˜λŠ” λ―Έλ―Έν•˜μ§€λ§Œ λ―Έμ·¨μ—…μ—¬μ„±κ³Ό μ·¨μ—…μ—¬μ„±μ˜ μΆ”κ°€ μΆœμ‚°μ˜ν–₯을 λ†’μ΄λŠ” κ²ƒμœΌλ‘œ λ‚˜νƒ€λ‚¬λ‹€. λ˜ν•œ 취업여뢀에 따라 각 독립 변인듀이 μΆ”κ°€ μΆœμ‚°μ˜ν–₯에 μƒμ΄ν•˜κ²Œ 영ν–₯을 λ―ΈμΉ˜λŠ” κ²ƒμœΌλ‘œ λ‚˜νƒ€λ‚¬λ‹€. 미취업여성은 경제적 νŠΉμ„±μ„ λ‚˜νƒ€λ‚΄λŠ” λ³€μˆ˜μΈ λ‚¨νŽΈμ˜ μ†Œλ“μ΄λ‚˜ 지역별 μ‹€μ—…λ₯  λ“±μ—μ„œ 영ν–₯을 λ°›λŠ” κ²ƒμœΌλ‘œ λ‚˜νƒ€λ‚¬λ‹€. 반면, μ·¨μ—…μ—¬μ„±μ˜ 경우 μž„κΈˆκ·Όλ‘œ 여뢀에 따라 의ν–₯의 차이λ₯Ό λ³΄μ˜€μœΌλ©°, λ³΄μœ‘μ‹œμ„€ 곡급λ₯ μ΄ μΆœμ‚°μ˜ν–₯에 λ―ΈμΉ˜λŠ” 영ν–₯ λ˜ν•œ 미취업여성에 λΉ„ν•΄ 큰 κ²ƒμœΌλ‘œ λ‚˜νƒ€λ‚˜ μžλ…€ μ–‘μœ‘κ³Ό κ΄€λ ¨λœ νŠΉμ„±μ΄ μ€‘μš”ν•˜κ²Œ 고렀되고 μžˆμŒμ„ νŒŒμ•…ν•  수 μžˆμ—ˆλ‹€. 결둠적으둜 λ³Έ μ—°κ΅¬λŠ” 싀증뢄석을 톡해 μ—¬μ„±μ˜ μ·¨μ—… μ—¬λΆ€ 및 지역별 νŠΉμ„±μ΄ μΆœμ‚°μ˜ν–₯에 영ν–₯을 쀄 수 μžˆμŒμ„ λ³΄μ˜€λ‹€. 이λ₯Ό λ°”νƒ•μœΌλ‘œ μΆœμ‚°μœ¨ 제고λ₯Ό μœ„ν•œ μ •μ±… 수립 μ‹œ μ—¬μ„±μ˜ μ·¨μ—…μ—¬λΆ€ 및 지역별 νŠΉμ„±μ„ κ³ λ €ν•œ μ°¨λ³„ν™”λœ 정책듀이 수립 및 μ‹œν–‰λ˜μ–΄μ•Ό ν•œλ‹€λŠ” 정책적 ν•¨μ˜λ₯Ό μ œμ‹œν•˜μ˜€λ‹€.제 1 μž₯ μ„œλ‘  1 1-1. 연ꡬ 동기 1 1-2. 연ꡬ 의의 3 제 2 μž₯ 이둠적 λ°°κ²½ 및 선행연ꡬ 4 2-1. κ²½μ œν•™μ  μ ‘κ·Ό 4 2-2. λ¬Έν™”κ°€μΉ˜κ΄€ μ ‘κ·Ό 6 2-3. 지역적 μ ‘κ·Ό 7 제 3 μž₯ 데이터 및 κΈ°μˆ ν†΅κ³„λŸ‰ 10 3-1. λΆ„μ„μžλ£Œ 10 3-2. κΈ°μˆ ν†΅κ³„λŸ‰ 11 제 4 μž₯ 연ꡬ방법 및 λ³€μˆ˜μ„€λͺ… 14 4-1. 연ꡬ방법 14 4-2. λ³€μˆ˜μ„€λͺ… 16 제 5 μž₯ 뢄석결과 20 5-1. 취업여뢀에 λ”°λ₯Έ μΆ”κ°€ μΆœμ‚°μ˜ν–₯ 20 5-2. κ²½μ œμ Β·λ¬Έν™”κ°€μΉ˜κ΄€ λ³€μˆ˜μ˜ 영ν–₯ 뢄석 21 5-3. λΆ€λͺ¨μ™€μ˜ 동거여뢀와 λ‚¨μ•„μ„ ν˜Έμ‚¬μƒμ˜ 관계 26 5-4. κ²½μ œμ Β·λ¬Έν™”κ°€μΉ˜κ΄€Β·μ§€μ—­μ  λ³€μˆ˜μ˜ 영ν–₯ 뢄석 27 제 6 μž₯ κ²°λ‘  및 ν•¨μ˜ 31Maste

    Effects of Post Ischemia-Reperfusion Treatment with Trimetazidine on Renal Injury in Rats: Insights on Delayed Renal Fibrosis Progression

    Get PDF
    Even after recovery from acute kidney injury, glomeruli remain vulnerable to further injury by way of interstitial fibrosis. This study is aimed at elucidating the effects of post ischemia-reperfusion (I/R) treatment with trimetazidine on the progression to renal fibrosis as well as short- and intermediate-term aspects. Trimetazidine 3 mg/kg or 0.9% saline was given intraperitoneally once upon reperfusion or daily thereafter for 5 d or 8 w. Renal histologic changes and related signaling proteins were assessed. After 24 h, post I/R treatment with trimetazidine significantly reduced serum blood urea nitrogen and creatinine levels and tubular injury accompanied with upregulation of hypoxia-inducible factor- (HIF-) 1Ξ±, vascular endothelial growth factor (VEGF), and Bcl-2 expression. After 5 d, post I/R treatment with trimetazidine reduced renal tubular cell necrosis and apoptosis with upregulation of HIF-1Ξ±-VEGF and tissue inhibitors of metalloproteinase activities, attenuation of matrix metalloproteinase activities, and alteration of the ratio of Bax to Bcl-2 levels. After 8 w, however, post I/R treatment with trimetazidine did not modify the progression of renal fibrosis. In conclusion, post I/R treatment with trimetazidine allows ischemic kidneys to regain renal function and structure more rapidly compared to nontreated kidneys, but not enough to resolute renal fibrosis in long-term aspect.ope

    Renoprotective effects of dexmedetomidine against ischemia-reperfusion injury in streptozotocin-induced diabetic rats.

    Get PDF
    BACKGROUND: Diabetic patients are susceptible to renal ischemia-reperfusion injury, which leads to perioperative complications. Activation of NOD-like receptor protein 3 (NLRP3) inflammasome participates in the development of diabetes, and contributes to renal ischemia-reperfusion injury. Dexmedetomidine (DEX), a highly selective Ξ±2-adrenoreceptor agonist, shows renoprotective effects against ischemia-reperfusion injury. We aimed to elucidate the effects, underlying mechanisms, and optimal timing of DEX treatment in diabetic rats. METHODS: Male Sprague-Dawley rats (n = 12 per group) were randomly divided into normal-sham, diabetes-sham, diabetes-ischemia-reperfusion-control, diabetes-ischemia-reperfusion-DEX-pre-treatment, and diabetes-ischemia-reperfusion-DEX-post-treatment groups. Renal ischemia-reperfusion injury was induced in diabetic rats by occlusion of both renal arteries for 45 min, followed by reperfusion for 24 h. DEX (10 ΞΌg/kg) was administered intraperitoneally 1 h before ischemia (pre-treatment) or upon reperfusion (post-treatment). After reperfusion, renal tissue was biochemically and histopathologically evaluated. RESULTS: DEX treatment attenuated ischemia reperfusion-induced increase in NLRP3, caspase-1, IL-1Ξ², phospho-AKT, and phospho-ERK signaling. Moreover, oxidative stress injury, inflammatory reactions, apoptosis, and renal tubular damage were favorably modulated by DEX treatment. Furthermore, post-reperfusion treatment with DEX was significantly more effective than pre-treatment in modulating NLRP3 inflammasome, AKT and ERK signaling, and oxidative stress. CONCLUSIONS: This study shows that the protective effects of DEX in renal ischemia-reperfusion injury are preserved in diabetic conditions and may potentially provide a basis for the use of DEX in clinical treatment of renal ischemia-reperfusion injury.ope

    Protective Effect of Ethyl Pyruvate against Myocardial Ischemia Reperfusion Injury through Regulations of ROS-Related NLRP3 Inflammasome Activation

    Get PDF
    Emerging evidence indicates the pronounced role of inflammasome activation linked to reactive oxygen species (ROS) in the sterile inflammatory response triggered by ischemia/reperfusion (I/R) injury. Ethyl pyruvate (EP) is an antioxidant and conveys myocardial protection against I/R injury, while the exact mechanisms remain elusive. We aimed to investigate the effect of EP on myocardial I/R injury through mechanisms related to ROS and inflammasome regulation. The rats were randomly assigned to four groups: (1) sham, (2) I/R-control (IRC), (3) EP-pretreatment + I/R, and (4) I/R + EP-posttreatment. I/R was induced by a 30 min ligation of the left anterior descending artery followed by 4 h of reperfusion. EP (50 mg/kg) was administered intraperitoneally at 1 h before ischemia (pretreatment) or upon reperfusion (posttreatment). Both pre- and post-EP treatment resulted in significant reductions in myocardial infarct size (by 34% and 31%, respectively) and neutrophil infiltration. I/R-induced myocardial expressions of NADPH oxidase-4, carnitine palmitoyltransferase 1A, and thioredoxin-interacting protein (TXNIP) were mitigated by EP. EP treatment was associated with diminished inflammasome activation (NOD-like receptor 3 (NLRP3), apoptosis-associated speck-like protein, and caspase-1) and interleukin-1Ξ² induced by I/R. I/R-induced phosphorylation of ERK and p38 were also mitigated with EP treatments. In H9c2 cells, hypoxia-induced TXNIP and NLRP3 expressions were inhibited by EP and to a lesser degree by U0126 (MEK inhibitor) and SB203580 (p38 inhibitor) as well. EP's downstream protective mechanisms in myocardial I/R injury would include mitigation of ROS-mediated NLRP3 inflammasome upregulation and its associated pathways, partly via inhibition of hypoxia-induced phosphorylation of ERK and p38.ope

    Effect of pregabalin administration upon reperfusion in a rat model of hyperglycemic stroke: Mechanistic insights associated with high-mobility group box 1

    Get PDF
    Hyperglycemia, which reduces the efficacy of treatments and worsens clinical outcomes, is common in stroke. Ability of pregabalin to reduce neuroexcitotoxicity may provide protection against stroke, even under hyperglycemia. We investigated its protective effect against hyperglycemic stroke and its possible molecular mechanisms. Male Wistar rats administered dextrose to cause hyperglycemia, underwent middle cerebral artery occlusion for 1 h and subsequent reperfusion. Rats were treated with an intraperitoneal injection of 30 mg/kg pregabalin or an equal amount of normal saline at the onset of reperfusion (n = 16 per group). At 24 h after reperfusion, neurological deficit, infarct volume, and apoptotic cell count were assessed. Western blot analysis was performed to determine protein expression of high-mobility group box 1 (HMGB1), toll-like receptor-4 (TLR-4), phosphorylated nuclear factor-kappa B (p-NF-ΞΊB), interleukin-1beta (IL-1Ξ²), tumor necrosis factor-alpha (TNF-Ξ±), phosphorylated inducible and endothelial nitric oxide synthase (p-iNOS, p-eNOS), Bcl-2, Bax, Cytochrome C, and caspase-3 in the brain. Pregabalin-treated rats showed significantly improved neurological function (31% decrease in score), reduced infarct size (by 33%), fewer apoptotic cells (by 63%), and lower expression levels of HMGB1, TLR4, p-NF-ΞΊB, IL-1Ξ², and TNF- Ξ±, compared with control rats. Decreased p-iNOS and increased p-eNOS expressions were also observed. Expression of Bax, Cytochrome C, and cleaved caspase-3/caspase3 was significantly downregulated, while Bcl-2 expression was increased by pregabalin treatment. Pregabalin administration upon reperfusion decreased neuronal death and improved neurological function in hyperglycemic stroke rats. Cogent mechanisms would include attenuation of HMGB1/TLR-4-mediated inflammation and favorable modulation of the NOS.ope

    Effects of propofol on the expression of matric metalloproteinases in rat cardiac fibroblasts after hypoxia and reoxygenation.

    Get PDF
    BACKGROUND: Propofol is known to protect the myocardium against ischaemia/reperfusion (I/R) injury through its antioxidant and anti-inflammatory properties. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are involved in cell migration and invasion, and mediate tissue remodelling during I/R injury. They are regulated by various mechanisms including oxidative stress and AKT and ERK pathways. We investigated whether propofol affected the expression of MMPs and subsequent cell migration and invasion and the signalling pathways involved in primary rat cardiac fibroblasts undergoing hypoxia and reoxygenation. METHODS: The phosphorylation of ERK and AKT signalling pathways was examined by western blot analysis in rat primary cardiac fibroblasts after hypoxia and reoxygenation. mRNA expression of MMP and TIMPS was analysed by real-time PCR, and proteolytic activities of MMP-2 and -9 were assessed. The effects of propofol on migration, invasion, wound healing, and cell proliferation activity were evaluated after reoxygenation. RESULTS: Propofol induced AKT and ERK1/2 activation. Subsequent activation of MMPs resulted in increased cell migration, invasion, and wound-healing activity under hypoxia-reoxygenation, which was decreased by LY294002 (AKT inhibitor) and U0126 (ERK inhibitor) in rat cardiac fibroblasts. However, propofol had no effect on proliferation or viability of cardiac fibroblasts after hypoxia-reoxygenation. CONCLUSIONS: Propofol affected the expression of MMPs and TIMPs and subsequently induced cell migration and invasive ability, through activation of the ERK and AKT signalling pathway in hypoxia-reoxygenated rat cardiac fibroblastsope

    A study on the Prevalence and Related Factors of Post-Intensive Care Syndrome(PICS) of Intensive Care Survivors

    No full text
    ν•™μœ„λ…Όλ¬Έ (석사)-- μ„œμšΈλŒ€ν•™κ΅ λŒ€ν•™μ› : κ°„ν˜Έν•™κ³Ό, 2017. 2. κ°•μŠΉμ™„.μ§‘μ€‘μΉ˜λ£Œ ν›„ 증후ꡰ(Post Intensive Care Syndrome: PICS)'은 쀑증 μ§ˆν™˜μ΄λ‚˜ κΈ‰μ„± μž…μ› 치료 ν›„ λ‚˜νƒ€λ‚˜λŠ” 볡합적인 μ¦μƒμœΌλ‘œμ„œ 이전보닀 μ•…ν™”λ˜κ±°λ‚˜ μƒˆλ‘œ μƒκ²¨λ‚œ 건강 문제둜 크게 신체적, 인지적, 정신적 μ¦μƒμœΌλ‘œ λ‚˜λ‰œλ‹€. λ³Έ μ—°κ΅¬λŠ” μ€‘ν™˜μž μƒμ‘΄μžμ˜ μ§‘μ€‘μΉ˜λ£Œ ν›„ μ¦ν›„κ΅°μ˜ μ‹€νƒœμ™€ κ΄€λ ¨μš”μΈμ„ νŒŒμ•…ν•˜κΈ° μœ„ν•œ μ„œμˆ μ  상관관계 연ꡬ이닀. μ—°κ΅¬μ˜ λͺ©μ μ€ μ€‘ν™˜μžκ΄€λ ¨ μ˜λ£Œμ§„ 및 건강관련 μ’…μ‚¬μž, μ€‘ν™˜μž μƒμ‘΄μžμ—κ²Œ μ§‘μ€‘μΉ˜λ£Œ ν›„ 증후ꡰ에 λŒ€ν•΄ μΈμ‹ν•˜κ²Œ ν•˜κ³  예방과 치료의 μ€‘μš”μ„±μ„ μ•Œλ € μ€‘ν™˜μžμ‹€ μƒμ‘΄μžμ˜ μ‚Άμ˜ μ§ˆμ„ μœ„ν•΄ μž₯기적으둜 관리할 수 μžˆλŠ” μ œλ„λ₯Ό λ§ˆλ ¨ν•˜λŠ” 것이닀. 자료 μˆ˜μ§‘μ€ 2016λ…„ 8μ›” 1일뢀터 9μ›” 30μΌκΉŒμ§€ μ„œμšΈ μ‹œλ‚΄ 일개 λŒ€ν•™λ³‘μ›μ˜ ν™˜μž 104λͺ…을 λŒ€μƒμœΌλ‘œ μ‹œν–‰ν•˜μ˜€λ‹€. μ§‘μ€‘μΉ˜λ£Œ ν›„ 증후ꡰ 츑정을 μœ„ν•΄ 신체적 κΈ°λŠ₯(K-ADL), 인지적 κΈ°λŠ₯(MMSE-K), 정신적 κΈ°λŠ₯(HADS, IES-R-K)의 κ΅¬μ‘°ν™”λœ 섀문지가 μ‚¬μš©λ˜μ—ˆλ‹€. μžλ£ŒλŠ” κΈ°μˆ ν†΅κ³„, t-test, one-way ANOVA, Pearsons correlation coefficient, Multiple regression 방법을 μ΄μš©ν•˜μ—¬ λΆ„μ„ν•˜μ˜€λ‹€. 연ꡬ κ²°κ³ΌλŠ” λ‹€μŒκ³Ό κ°™λ‹€. 1. μ€‘ν™˜μž μƒμ‘΄μž 쀑 89λͺ…(85.6%)이 μ§‘μ€‘μΉ˜λ£Œ ν›„ 증후ꡰ에 ν•΄λ‹Ήν•˜μ˜€κ³ , 이듀은 λ³Έ μ—°κ΅¬μ—μ„œ μΈ‘μ •ν•œ 5개의 증상 쀑 평균 2개의 증상을 κ²½ν—˜ ν•˜λŠ” κ²ƒμœΌλ‘œ λ‚˜νƒ€λ‚¬λ‹€. λ˜ν•œ PICS 증상 쀑 인지적 Β· 신체적 λ¬Έμ œμ— λΉ„ν•΄ 정신적 문제(λΆˆμ•ˆ, 우울, PTSD)κ°€ 많이 λ°œμƒν•˜μ˜€λ‹€. 2. K-ADL둜 μΈ‘μ •ν•œ 신체기λŠ₯μž₯μ• κ°€ μžˆλŠ” λŒ€μƒμžλŠ” 28λͺ…(26.9%), MMSE-K둜 μΈ‘μ •ν•œ 인지기λŠ₯μž₯μ• κ°€ μ˜μ‹¬λ˜κ±°λ‚˜ 인지기λŠ₯μž₯μ• κ°€ μžˆλŠ” λŒ€μƒμžλŠ” 30λͺ…(28.9%)μ΄μ—ˆλ‹€. HADS둜 μΈ‘μ •ν•œ λΆˆμ•ˆ 증상을 ν˜Έμ†Œν•˜λŠ” λŒ€μƒμžλŠ” 총 36λͺ…(34.7%), 우울 증상을 ν˜Έμ†Œν•˜λŠ” λŒ€μƒμžλŠ” 총 75λͺ…(72.1%)μ΄μ—ˆλ‹€. IES-R-K둜 μΈ‘μ •ν•œ PTSDλ₯Ό 호 μ†Œν•˜λŠ” λŒ€μƒμžλŠ” 총 38λͺ…(36.5%)μ΄μ—ˆλ‹€. 3. 신체적 Β· 인지적 Β· 정신적 증상에 μœ μ˜ν•œ 차이가 μžˆλŠ” κ²ƒμœΌλ‘œ λ‚˜νƒ€λ‚œ λŒ€μƒμžμ˜ μ§ˆλ³‘ νŠΉμ„±μ€ λ‹€μŒκ³Ό κ°™λ‹€. μΌμƒμƒν™œκΈ°λŠ₯은 패혈증 (p=.047), μ€‘ν™˜μžμ‹€ μž¬μ› 일수(p=.020), μŠΉμ••μ œ(p=.031)μ—μ„œ, 인지기λŠ₯은 μ§ˆλ³‘μ€‘μ¦λ„(p<.001), μ€‘ν™˜μžμ‹€ μž… Β· 퇴싀 μ‹œ μ˜μ‹μˆ˜μ€€(p=.045, p<.001)μ—μ„œ, λΆˆμ•ˆμ€ 패혈증(p=.042), μš°μšΈμ€ 지속적 인슐린(p=.002),μŠ€ν…Œλ‘œμ΄λ“œ 치료(p=.004), PTSDλŠ” μ€‘ν™˜μžμ‹€ μž…μ‹€ 횟수(p=.012)μ—μ„œ μœ μ˜ν•œ 차이λ₯Ό λ³΄μ˜€λ‹€. 4. PICS에 영ν–₯을 λ―ΈμΉ˜λŠ” μš”μΈμ€ μŠ€ν…Œλ‘œμ΄λ“œ 치료(p<.001), μ§ˆλ³‘μ€‘μ¦λ„(p=.010), 성별(p=.011), 지속적 인슐린 치료(p=.022)μ˜€μœΌλ©° 이 λ³€μˆ˜λ“€μ€ PICSλ₯Ό 33.7% μ„€λͺ…ν•˜μ˜€λ‹€. λ³Έ μ—°κ΅¬μ—μ„œ μŠ€ν…Œλ‘œμ΄λ“œμ™€ 지속적 인슐린 μΉ˜λ£ŒλŠ” PICS의 증상을 κ°μ†Œμ‹œν‚€λŠ” μš”μΈμœΌλ‘œ λ‚˜νƒ€λ‚¬λ‹€. λ˜ν•œ 쀑증도가 λ†’μ„μˆ˜λ‘, λ‚¨μžλ³΄λ‹€ μ—¬μžκ°€ PICS의 증상을 더 많이 κ²½ν—˜ν•˜λŠ” κ²ƒμœΌλ‘œ λ‚˜νƒ€λ‚¬λ‹€. κ΅­λ‚΄μ—μ„œλŠ” PICS의 μ‹€νƒœλ₯Ό νŒŒμ•…ν•œ 연ꡬ가 λ“œλ¬ΌκΈ°μ— μ§€μ—­μ‚¬νšŒ, 병원, κ°€μ • λ“± λ‹€μ–‘ν•œ ν™˜κ²½μ— μžˆλŠ” μ€‘ν™˜μž μƒμ‘΄μžλ₯Ό λŒ€μƒμœΌλ‘œ 반볡 연ꡬ가 ν•„μš”ν•˜λ‹€. λ˜ν•œ μ€‘ν™˜μž μ˜λ£Œμ§„μ€ μ€‘ν™˜μž μƒμ‘΄μžκ°€ 더 λ‚˜μ€ μ‚Άμ˜ μ§ˆμ„ μ˜μœ„ν•  수 μžˆλ„λ‘ PICS에 영ν–₯을 λ―ΈμΉ˜λŠ” κ΄€λ ¨ μš”μΈμ„ νŒŒμ•…ν•˜μ—¬ PICS의 λ°œμƒμ„ 쀄일 수 μžˆλ„λ‘ λ…Έλ ₯ν•΄μ•Ό ν•  것이닀. μ£Όμš”μ–΄: μ€‘ν™˜μžμ‹€, μ€‘ν™˜μž μƒμ‘΄μž, μ§‘μ€‘μΉ˜λ£Œ ν›„ 증후ꡰ ν•™ 번: 2015-20552I. μ„œλ‘  1 1. 연ꡬ ν•„μš”μ„± 1 2. 연ꡬ λͺ©μ  4 3. μš©μ–΄ μ •μ˜ 4 II. λ¬Έν—Œκ³ μ°° 6 1. μ€‘ν™˜μžμ‹€ ν™˜μžμ˜ κ²½ν—˜ 6 2. μ§‘μ€‘μΉ˜λ£Œ ν›„ 증후ꡰ 9 III. μ—°κ΅¬μ˜ 이둠적 κΈ°ν‹€ 18 1. λ‚˜μ΄νŒ…κ²ŒμΌ ν™˜κ²½μ΄λ‘  18 2. λ³Έ μ—°κ΅¬μ˜ 이둠적 κΈ°ν‹€ 19 IV. 연ꡬ 방법 21 1. 연ꡬ 섀계 21 2. 연ꡬ λŒ€μƒ 및 κΈ°κ°„ 21 3. 연ꡬ 도ꡬ 22 4. 자료 μˆ˜μ§‘ 방법 및 절차 26 5. 자료 뢄석 방법 26 6. 윀리적 κ³ λ € 27 7. μ—°κ΅¬μ˜ μ œν•œμ  28 V. 연ꡬ결과 29 1. λŒ€μƒμž νŠΉμ„± 29 2. μ§‘μ€‘μΉ˜λ£Œ ν›„ 증후ꡰ 40 3. μ§ˆλ³‘ νŠΉμ„±μ— λ”°λ₯Έ μΌμƒμƒν™œκΈ°λŠ₯, λΆˆμ•ˆ, 우울, PTSD, 인지기λŠ₯ 43 4. λŒ€μƒμž νŠΉμ„±μ— λ”°λ₯Έ μ§‘μ€‘μΉ˜λ£Œ ν›„ 증후ꡰ 48 5. μ§‘μ€‘μΉ˜λ£Œ ν›„ 증후ꡰ 증상 κ°„μ˜ 상관관계 55 6. μ§‘μ€‘μΉ˜λ£Œ ν›„ 증후ꡰ에 영ν–₯을 λ―ΈμΉ˜λŠ” μš”μΈ 57 VI. λ…Ό 의 59 1. μ§‘μ€‘μΉ˜λ£Œ ν›„ μ¦ν›„κ΅°μ˜ μ‹€νƒœ 59 2. μ§‘μ€‘μΉ˜λ£Œ ν›„ μ¦ν›„κ΅°μ˜ κ΄€λ ¨μš”μΈ 62 VII. κ²°λ‘  및 μ œμ–Έ 66 1. κ²° λ‘  66 2. 제 μ–Έ 68 μ°Έκ³ λ¬Έν—Œ 69 λΆ€ 둝 81 Abstract 92Maste

    쑰골세포 λΆ„ν™”μ—μ„œ ERK 12 ν†΅ν•œ Runx2 μ•ˆμ •μ„± μ‘°μ ˆμ— κ΄€ν•œ 연ꡬ

    No full text
    Thesis(doctors) --μ„œμšΈλŒ€ν•™κ΅ λŒ€ν•™μ› :μΉ˜μ˜ν•™κ³Ό(λ‘κ°œμ•…μ•ˆλ©΄ 세포 및 λ°œμƒμƒλ¬Όν•™μ „κ³΅),2008. 8.Docto

    Nano-fibrous scaffolding promotes osteoblast differentiation and biomineralization

    No full text
    Nano-fibrous poly(l-lactic acid) (PLLA) scaffolds with interconnected pores were developed under the hypothesis that nano-fibrous scaffolding would mimic a morphological function of collagen fibrils to create a more favorable microenvironment for cells versus solid-walled scaffolds. In this study, an in vitro system was used to examine biological properties of the nano-fibrous scaffolds compared with those of solid-walled scaffolds for their potential use in bone tissue engineering. Biomineralization was enhanced substantially on the nano-fibous scaffolds compared to solid-walled scaffolds, and this was confirmed by von Kossa staining, measurement of calcium contents, and transmission electron microscopy. In support of this finding, osteoblasts cultured on the nano-fibrous scaffolds exhibited higher alkaline phosphatase activity and an earlier and enhanced expression of the osteoblast phenotype versus solid-walled scaffolds. Most notable were the increases in runx2 protein and in bone sialoprotein mRNA in cells cultured on nano-fibrous scaffolds versus solid-walled scaffolds. At the day 1 of culture, Ξ±2 and Ξ²1 integrins as well as Ξ±v and Ξ²3 integrins were highly expressed on the surface of cells seeded on nano-fibrous scaffolds, and linked to this were higher levels of phospho-Paxillin and phospho-FAK in cell lysates. In contrast, cells seeded on solid-walled scaffolds expressed significantly lower levels of these integrins, phospho-Paxillin, and phospho-FAK. To further examine the role of nano-fibrous architecture, we inhibited the formation of collagen fibrils by adding 3,4-dehydroproline to cultures and then assayed cells for expression of Ξ±2 integrin. Cells seeded on nano-fibrous scaffolds sustained expression of Ξ±2 integrin in the presence of dehydroproline, while suppression of Ξ±2 integrin was evident in cells seeded on solid-walled scaffolds. These results provide initial evidence that synthetic nano fibers may exhibit certain properties that are comparable to natural collagen fibers, and thus, the nano-fibrous architecture may serve as a superior scaffolding versus solid-walled architecture for promoting osteoblast differentiation and biomineralization.ope
    corecore